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Pharmacokinetics of ARC-520 Injection,
an RNA Interference-Based
Therapeutic for the Treatment
of Chronic Hepatitis B Virus Infection,
in Healthy Volunteers
Thomas Schluep1, Jason Lickliter2, James Hamilton1, David L. Lewis1, Ching-Lung Lai3,
Johnson YN Lau4, Stephen A. Locarnini5, Robert G.Gish6, and Bruce D.Given1
Abstract
ARC-520 Injection, an RNA interference drug for the treatment of hepatitis B that targets cccDNA-derived viral mRNA
transcripts with high specificity, effectively reduces the production of viral proteins and HBV DNA. In this phase 1
randomized, double-blind, placebo-controlled study, 54 healthy volunteers (half male, half female) received a single, in-
travenous dose of 0.01–4.0 mg/kg ARC-520 Injection (n = 36) or placebo (n = 18). Assessments included safety, tol-
erability, pharmacokinetics, and pharmacodynamics (cytokines and complement). Pharmacokinetics of the siRNA and
peptide excipient components contained in ARC-520 Injection showed a relatively short half-life of 3–5 and 8–10 hours,
respectively. Dose exposure linearity was demonstrated within the dose range. ARC-520 Injection was well tolerated,
with adverse-event frequency the same as placebo and no serious adverse events. ARC-520 Injection was initially found
to induce histamine release through mast cell degranulation, resulting in 2 moderate hypersensitivity reactions. How-
ever, after initiation of pretreatment with oral antihistamine, no further hypersensitivity reactions occurred. Low-level,
transient complement induction and sporadic, mild, and transient elevations of several cytokines were observed but
not associated with any symptoms. ARC-520 Injection showed a favorable tolerability profile in this single-dose study
in healthy volunteers. Oral antihistamine pretreatment is recommended in the future to offset mast cell degranulation
stimulation.
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With an estimated 240–400 million people worldwide
chronically infected with the hepatitis B virus (HBV)
and more than 750 000 deaths annually from HBV-
related complications,1–5 therapies that can induce high
rates of hepatitis B surface antigen (HBsAg) sero-
clearance, an outcome associated with a much im-
proved prognosis, are very desirable. Although current
therapies, nucleos(t)ide analog reverse-transcriptase in-
hibitors (NUCs) and interferon (IFN), decrease the risk
of liver decompensation and improve survival,6–8 clear-
ance of HBsAg is uncommon. Because discontinuation
of NUC therapy results in a high rate of viral rebound
and biochemical relapse6,9–12 and a long-term increased
risk of hepatocellular carcinoma,13 lifelong NUC
therapy is currently recommended formost patients. In-
novative therapies that could induce high rates of HB-
sAg seroclearance, thus reducing off-treatment disease
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progression and allowing safe discontinuation of indef-
inite NUC therapy, are needed.
Therapies based on RNA interference (RNAi) can
directly target hepatitis B virus mRNA transcripts with
high specificity, profoundly reducing the production of
viral proteins, including HBsAg, and potentially al-
lowing restoration of effective host immunity. RNAi
uses small, noncoding RNA to regulate the expres-
sion of genetic information.14 The RNAi-based drug
ARC-520 Injection consists of 2 synthetic short in-
terfering RNAs (siRNAs) conjugated to cholesterol,
which enhances delivery of the siRNA to hepato-
cytes. ARC-520 Injection uses a polymer-based sys-
tem, Dynamic PolyConjugates (DPC), for the targeted
delivery of siRNA to hepatocyte cytoplasm, where
RNAi occurs.15 DPCs use an amphipathic, membrane
active peptide, melittin-like peptide (MLP), which is
reversibly masked so that the polymer’s membrane ac-
tivity is only revealed in the acidic environment of
the endosome. The masking agent includes the tar-
geting ligand N-acetylgalactosamine (NAG), causing
hepatocyte-specific delivery via the highly expressed
asialoglycoprotein receptor present on the surface of
hepatocytes.16 Intravenous coinjection of cholesterol-
conjugated siRNA with the liver-targeted DPC com-
ponent results in efficient endosomal escape and
cytoplasmic delivery of siRNA to hepatocytes, limiting
the toxicity that could result from interaction with non-
targeted cells.
The organization of the HBV genome makes it an
attractive target for the use of RNAi. HBV persists in
the nucleus of hepatocytes as a minichromosome, cova-
lently closed circular DNA (cccDNA), which serves as
the template for 5 overlapping viral transcripts includ-
ing pregenomic RNA.17 Because all viral transcripts
expressed from cccDNA share the same termination
codon, a single RNAi trigger can target all viral RNA
for degradation. The siRNA sequences AD0009 and
AD0010 are shown in Table 1. Their selection process
and target region within the open-reading frame of
the HBV X protein have been previously described.18
This screening process included a step to eliminate se-
quences with close similarities to RNA of the human
transcriptome. Because ARC-520 Injection contains
2 siRNAs (AD0009 and AD0010) targeted toward
cccDNA-derived transcripts, it has more extensive
genotype coverage than would occur with a single
RNAi trigger. AD0009 and AD0010 are an identical
match to their target sequence in 96.4% and 92.6%, re-
spectively, of all surveyed HBV genomes; the combi-
nation provides coverage of 99.64%18 and reduces the
frequency of escape mutants that might arise during
treatment because such mutants would need to ac-
cumulate at least 2 resistance mutations, one in each
target sequence. In addition, the RNAi triggers in
ARC-520 Injection were chemically modified using
sugar and backbone analogues to increase nuclease re-
sistance and minimize the potential for induction of an
innate immune response.19–23
Using a transiently transgenic pHBV mouse model
generated by hydrodynamic tail vein injection of a
plasmid harboring the terminally redundant full-length
HBV genome (HBV 1.3),24 it was found that the
RNAi triggers were very effective when coinjected with
NAG-MLP, with decreases in HBsAg expression of
between 2 and 3 log10 after a single intravenous in-
jection, along with substantial decreases in HBeAg,
serum HBV DNA, and liver levels of HBV RNA.18
No knockdown was observed when the RNAi triggers
were injected without NAG-MLP and vice versa, in-
dicating that NAG-MLP is necessary for effective cy-
toplasmic delivery and that knockdown is HBV RNAi
trigger–dependent. We report here the first clinical as-
sessment of treatment with ARC-520 Injection in a
study designed to evaluate the safety, tolerability, and
pharmacokinetics to help determine the dosage range
appropriate for study in subsequent clinical trials in
patients with chronic HBV infection.
Subjects and Methods
Study Design
This was a single-center, randomized, double-blind,
placebo-controlled, sequential, single-dose-escalation,
first-in-human phase 1 study conducted to evaluate
the safety, tolerability, and pharmacokinetics of the
investigational product ARC-520 Injection adminis-
tered intravenously to a healthy volunteer population
of adults (the Heparc-1001 study; Clinicaltrials.gov
registration number: NCT01872065). The study was
conducted at Nucleus Network, a single center in Mel-
bourne, Australia, with recruitment of subjects start-
ing in July 2013 and database closure in October 2014,
with the exception of a follow-up telephone call for co-
hort 9, which was completed in November 2014. Eligi-
ble subjects were enrolled sequentially into 9 cohorts,
with 6 subjects per cohort, and randomized with a
4:2 (active:placebo) ratio. Each subject was assigned
to either active (ARC-520 Injection) or placebo (0.9%
normal saline) treatment using a block randomiza-
tion algorithm. Final confirmation of eligibility was
checked on day 1. Because of slight color differences
between placebo and ARC-520 Injection, the syringes
were blinded with translucent labels to mask the in-
fusate identity to the blinded staff and participants.
Other than pharmacists and staff involved in random-
ization, dispensing and preparation of the study drug
remained blinded. At the completion of the planned
initial 6 cohorts through 29 days of follow-up, the de-
cision was made to unblind the study to assess whether
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Table 1. Cholesterol-RNAi Triggers AD0009 and AD0010 Used in the Study





Underline represents hybridization region.
Lower case letter, 2’O-Me substitution; Nf, 2’F substitution; N, ribose; dN, deoxyribose; invdT, inverted deoxythymidine; s, phosphorothioate bond;
Chol, cholesterol.
it was safe and appropriate to continue to enroll fur-
ther cohorts at higher doses. All data were cleaned and
queries returned on the first 6 cohorts before database
lock. Unblinding each cohort was self-contained, and
it was not believed that unblinding the first 6 cohorts
would bias evaluation of subsequent cohorts.
Cohorts 1–6 and 8–9 were initiated with a sentinel
group of 2 subjects (1 randomized to placebo and 1 to
ARC-520 Injection). After review by the Data Safety
Monitoring Committee (DSMC; composed of the pri-
mary investigator [PI] and medical monitor) of the sen-
tinel group’s safety and tolerability data through day 3,
the remaining 4 subjects in the cohort were random-
ized and treated on the same day. For cohort 7, which
had the same dose as cohort 6, 6 eligible subjects re-
ceived ARC-520 Injection or placebo on the same day,
with no sentinel group. The safety data through day
3 for an entire completed cohort of subjects was also
reviewed prior to enrollment and dosing of the next
cohort. DSMC safety review minutes and recom-
mendations were submitted to the independent ethics
committee as a notification prior to dosing of the
next cohort. There was no intrasubject dose escalation.
Subjects fasted from food for at least 8 hours predose
and 4 hours postdose and from water from 1 hour pre-
dose to 1 hour postdose. Blood samples were collected
predose and at specified times after dosing to determine
pharmacokinetic (PK) parameters and pharmacody-
namic (PD) end points (cytokines and complement).
After 2 participants developed limited rashes (1 mild,
1 moderate) during dose administration, the decision
was made that participants in cohorts 7–9 would be
pretreated with antihistamine (diphenhydramine 50 mg
orally) 2 hours prior to treatment administration.
Subjects were confined at the clinical facility from
day 1 to the morning of day 2 and then discharged fol-
lowing completion of safety assessments and blood and
urine sampling. Visits to the clinical facility occurred on
days 3, 4, 8, 15 ± 1 and 29 ± 1 (end-of-study visit). A
telephone follow-up occurred on day 90 ± 5 to verify
compliance with contraceptive measures and absence
of any known pregnancy. Clinically significant changes
including adverse events (AEs) were followed until res-
olution or grade 1 status was achieved. The study was
performed in accordance with the 2008 Declaration of
Helsinki25 and good clinical practice guidelines. The
study was approved by the Alfred Hospital ethics com-
mittee (The Alfred Hospital, Melbourne, Australia).
All subjects gave written informed consent before
screening.
Participants
Potential subjects recruited from the Melbourne area
underwent screening to confirm eligibility andwere ran-
domized during the 21 days prior to the scheduled dos-
ing date. Healthy male or female subjects 18 to 55 years
old who were nonsmokers were eligible to participate.
Exclusion criteria included history of clinically rele-
vant medical illnesses that in the Investigator’s opinion
might jeopardize subject safety or interfere with partic-
ipation in the study, including but not limited to hema-
tological, renal, endocrine, pulmonary, gastrointestinal,
cardiovascular, hepatic, psychiatric, neurologic, or al-
lergic disease; acute signs of hepatitis/other infection
(eg,moderate fever, jaundice, nausea, vomiting, abdom-
inal pain) evident within 4 weeks of screening and/or
at the screening examination; use of any drugs known
to induce or inhibit hepatic drug metabolism within
30 days prior to administration of study treatment;
being seropositive for human immunodeficiency virus,
HBV (HBsAg positive), or hepatitis C virus; current
use and/or a history of alcohol and/or drug abuse < 12
months from screening; use of investigational agents or
devices within 30 days prior to planned study dosing
or current participation in an investigational study; a
history of allergy to bee venom, history of hypersensi-
tivity reaction requiring an emergency visit to a physi-
cian or hospital and/or requirement for treatment with
steroids and/or epinephrine, or a positive reaction to
the bee venom allergy skin test performed at screen-
ing. The bee venom exclusion criterion was included
because the MLP component of the ARC-520 Injec-
tion is similar to melittin, a component of honey bee
venom and therefore could theoretically cause an al-
lergic reaction in patients with a history of bee sting
allergy.
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Participants were free to withdraw from the study
at any time for any reason. The PI could withdraw a
subject to protect his/her health if the need to take
medication could interfere with study measurements;
intolerable/unacceptable adverse experiences occurred;
major violation or deviation of study protocol proce-
dures occurred; there was noncompliance of subject
with protocol; the subject was unwilling to proceed,
and/or consent was withdrawn; or if it was deemed in
the subject’s best interest.
Treatments
Test Formulation. The ARC-520 Injection was ad-
ministered as a single intravenous infusion at ascend-
ing doses of 0.01, 0.1, 0.3, 0.6, 1.2, 2.0, 3.0, and
4.0 mg/kg. Arrowhead Pharmaceuticals, Inc.
(Pasadena, California) supplied the ARC-520 In-
jection as 2 sterile 10-mL vials containing ARC-520
API (the active pharmaceutical ingredient: siRNAs
AD0009 and AD0010) and ARC-EX1 (the delivery
excipient). The API is composed of a 1:1 molar
mixture of 2 synthetic, double-stranded, cholesterol-
conjugated RNA oligonucleotides. ARC-EX1 is a
masked, hepatocyte-targeted polymeric amine (poly-
meric amine = L-melittin-derived peptide; masking
group = carboxydimethyl maleic anhydride N-acetyl
galactosamine [NAG-MLP]).18 Prior to dosing sub-
jects, a study pharmacist mixed 1 vial of ARC-EX1
with 1 vial of API to yield the ARC-520 Injection.
Reference Formulation. Placebo: normal saline (0.9%).
Antihistamine. The oral antihistamine diphenhy-
dramine hydrochloride 50-mg gel capsules (Unisom
Sleep Gel Cap; Petrus Pharmaceuticals, Australia)
were supplied to cohorts 7–9; all antihistamine doses
were given with 250 mL of water at least 2 hours prior
to study drug administration for cohorts 7, 8, and 9
only.
Each subject received a single dose of ARC-520 In-
jection or placebo administered intravenously by clini-
cal staff at the infusion rate indicated in Table 2.
Safety Assessments
The safety analysis included all patients who were ran-
domized and received study medication. Safety mea-
sures included (1) AEs; (2) physical examinations;
(3) vital signs (resting heart rate, semi-supine sys-
tolic/diastolic blood pressure, respiratory rate, and
temperature); (4) triplicate electrocardiogram (ECG)
measurements at least 2 minutes apart (readings taken
after the subject was supine for at least 3 minutes);
(5) clinical laboratory tests (hematology, biochemistry,
coagulation, urinalysis); (6) use of concomitant medi-
cations; and (7) recording reasons for treatment discon-
tinuation because of toxicity. In addition, continuous
monitoring by ECG telemetry was used from within
Table 2. Dose and Infusion Rates for Cohorts 1–9
Cohort Dose (mg/kg) Pretreatment Infusion Rate
Cohort 1 0.01 None Slow pusha
Cohort 2 0.10 None Slow pusha
Cohort 3 0.30 None 7 mL/min
Cohort 4 0.60 None 3.5 mL/min
Cohort 5 1.20 None 3.5 mL/min
Cohort 6 2.00 None 3.5 mL/min
Cohort 7 2.00 Oral antihistamine 2 mL/minb
Cohort 8 3.00 Oral antihistamine 2 mL/minb
Cohort 9 4.00 Oral antihistamine 2 mL/minb
Each subject received a single dose of either active drug (ARC-520 Injec-
tion) or placebo (normal saline 0.9%) administered intravenously at the
infusion rate indicated.
aInitial volumes for cohorts 1–2 were too small to administer using sy-
ringe pump infusion as planned in the protocol; thus, they were given by
slow push.
bThe infusion rate for cohorts 7–9 was reduced from 3.5 to 2 mL/min
at the overlapping dose of 2 mg/kg to lessen risk of infusion reaction.
1 hour predose through 24 hours postdose for all en-
rolled subjects during dosing with ARC-520 Injection
or placebo.
Abnormalities in laboratory findings or other assess-
ments that were deemed clinically significant by the PI
and were initially detected during the study or were
present at baseline and significantly worsened during
the study were reported as AEs, whether or not they
were considered drug related. The causality of AEs was
determined by the principal investigator. All AEs and
serious AEs (SAEs) were followed until resolution, un-
til the condition stabilized, until the event was otherwise
explained, or until the subject was lost to follow-up.
Pharmacokinetic Assessments
Eight blood samples were collected from each subject
during the study for pharmacokinetic analysis. Ap-
proximately 4 mL of whole blood was collected using
ethylenediaminetetraacetic acid (EDTA) as an antico-
agulant. Samples were centrifuged at 4°C, and plasma
was stored at -20°C until transfer to the bioanalytical
laboratory. Plasma samples were assayed by a validated
liquid chromatography with fluorescence detection
method for the ARC-520 siRNAs.26 The sequences
for the siRNAs AD0009 and AD0010 are shown in
Table 1. In this method, siRNAs are first hybridized
with a fluorescently labeled peptide nucleic acid
(PNA)27 probe complementary to the antisense
strand, and the resulting complex is analyzed
by high-pressure liquid chromatography (HPLC)
with fluorescence detection. Briefly, thawed plasma
samples were resolubilized in lysis buffer contain-
ing 50 μg/mL proteinase K. Sequence-specific
PNA probes were generated for RNAi triggers
AD0009 (Atto425-OO-CTGTAGGCATAAATT) and
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AD0010 (Atto425-OO-ACCTCTGCCTAATCA),
(Panagene, Daejeon, Korea), which bound to the anti-
sense strand of each RNAi trigger. These contained the
fluorescent Atto425 label at the N-terminus, separated
from the PNA chain by a diethylene glycol linker. One
PNA probe was added to each supernatant sample. Hy-
bridization of the probe to the antisense siRNA strand
was performed in 96-well conical-bottom plates. Plates
were sealed and incubated at 95°C for 15 minutes in a
thermal cycler. Plates were rapidly cooled to 20°C by
incubating in an ice bath. HPLC analysis was carried
out using a Shimadzu HPLC system with a DNAPac
PA-100 4 × 250-mm analytical column (Fisher Scien-
tific, Pittsburgh, Pennsylvania). Analysis was carried
out at a flow rate of 1 mL/min with a column oven
temperature of 60°C. A gradient elution from 9% to
13% mobile phase B over 5 minutes was used with
mobile phase A (1 mM EDTA in 25 mM Tris-HCl
[pH 8.0], 50% acetonitrile) and mobile phase B (1 mM
EDTA and 1.6MNaClO4 in 25 mMTris-HCl [pH 8.0],
50% acetonitrile). Fluorescence detection was set to
436-nm excitation and 484-nm emission. The range of
the method was 1.0 to 100 ng/mL for both AD0009
and AD0010, using a 25-μL aliquot of human plasma.
For AD0009, intraday precision and accuracy were
between 1.8% and 10.9% coefficient of variation (CV)
and between 89.9% and 110.0% of theoretical, respec-
tively. Interday precision and accuracy were between
4.0% and 9.2% CV and between 97.5% and 103.6%
of theoretical, respectively. For AD0010, intraday
precision and accuracy were between 2.3% and 12.2%
CV and between 93.2% and 108.0% of theoretical,
respectively. Interday precision and accuracy were
between 3.7% and 7.9% CV and between 98.4% and
101.6% of theoretical, respectively.
A validated liquid chromatography–tandem mass
spectrometry method was used for the excipient peptide
(MLP). This method initially converts NAG-MLP into
unmasked MLP via acid hydrolysis. MLP with the se-
quence LIGAILKVLATGLPTLISWIKNKRKQ and
its internal standard, a synthetic MLP peptide with
5 heavy isotope-labeled leucine amino acids (Leu:
U13C6, 15N), were then extracted from human plasma
using solid-phase extraction (Oasis HLB 1 cc; Waters).
The analytes were separated by HPLC on a Zorbax
300SB C18 reverse-phase column (2.1 × 150-mm, Ag-
ilent), using a gradient of 34% acetonitrile, 0.1 TFA in
water to 62% acetonitrile, 0.1% TFA in water at a flow
rate of 0.3 mL/min over 5 minutes at 50°C. The eluates
are monitored by an API 4000 tandem mass spectrom-
etry detector (Sciex) in positive MRM mode. The mul-
tiple charged Q1/Q3 transition was 719.8/884.0 mass to
charge (m/z) for MLP and 728.7/893.2 m/z for the in-
ternal standard. The data are acquired and processed
by the data acquisition system Analyst (AB Sciex). The
range of the method is 10.0 to 10 000 ng/mL, using a
100-μL aliquot of human plasma. Intraday precision
and accuracy were between 1.4% and 4.6% CV and be-
tween 98.5% to 101.7% of theoretical, respectively. In-
terday precision and accuracy were between 3.2% and
11.3% CV and between 100.7% and 108.0% of theoret-
ical, respectively. Plasma concentrations of ARC-520
API (siRNAs) and MLP (excipient peptide) were de-
termined at different doses. Plasma concentrations of
ARC-520 components were used to calculate single-
dose pharmacokinetic parameters. Samples of all sub-
jects were analyzed.
Pharmacodynamic Assessments
Whole blood was collected at specified times for analy-
sis of cytokines and complement.
Cytokines. Whole-blood samples were processed for
serum. Serum was stored at -20°C until transfer to the
bioanalytical laboratory and was analyzed by Luminex
assay for the following cytokine panel: IL-6, MCP-1,
TNF-α, IL-8, IL-1β, IFN-α, and MIP-1α. Initially
the 0- (pre-) and 6-hour postdose samples were ana-
lyzed, with the remaining samples analyzed if a change
from baseline was observed at 6 hours. Cytokines were
chosen based on literature data on innate immune
responses and cytokines induced by double-stranded
RNA and phosphorothioate oligonucleotides.28,29
Complement. Venous blood samples were collected
and processed to produce serum (for complementCH50
analysis) or plasma (for split products–Bb analysis).
Initially the 0- (pre-) and 0.5-hour postdose samples
were analyzed, with the remaining samples analyzed if
a change from baseline was observed at 0.5 hours.
Statistical Analysis
All study subjects receiving any test article were in-
cluded in the safety analyses. Treatment-emergent AEs
were summarized using the latest version of MedDRA
by system organ class (SOC) and preferred term (PT).
Laboratory results were classified according to Na-
tional Cancer Institute Common Terminology Crite-
ria for Adverse Events and summarized by treatment
group. Vital sign measurements were summarized at
each scheduled point using descriptive statistics. ECG
parameter changes overall, changes from baseline, and
qualitative assessments were summarized. Pharmacoki-
netic data were presented for all subjects who were
administered ARC-520 Injection. Plasma concentra-
tions less than the limit of quantitation of the as-
say were designated a value of zero for pharmacoki-
netic analysis and included in the calculation of the
means. The pharmacokinetic parameters were deter-
mined using noncompartmental method(s). Descrip-
tive statistics of pharmacokinetic parameters included
mean, standard deviation (SD), and CV, minimum and
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maximum. Dose-related trends in pharmacokinetic pa-
rameters were assessed. PhoenixWinNonlin version 6.3
(1998–2012; Certara L.P., distributed by Pharsight Cor-
poration) was used for pharmacokinetic analysis. SAS
9.2 (SAS Institute Inc., Cary, North Carolina) was used
for statistical analysis, including generating data listings
and summary tables.
In Vitro Mast Cell Degranulation Studies
Rat and human mast cell degranulation assays were
performed as previously described.30 Briefly, freshly
isolated rat peritoneal mast cells were resuspended in
RPMIMedium 1640 containing 1% fetal bovine serum
(FBS) and incubated with ARC-EX1, ARC-520 API,
the combination of the two, or positive controls (IgE-
DNP or Compound 48/80) at increasing concentra-
tions up to 250 μg/mL for ARC-EX1 or 1000 μg/mL
for ARC-520 API. Incubation was at 37°C for 10 or
30 minutes, after which supernatants were analyzed for
histamine and chymase release as a measure of degran-
ulation and lactate dehydrogenase (LDH) release as a
measure of viability.
The human mast cell line HMC-1 was cultured in
Iscove’s media containing 2% FBS and incubated with
ARC-EX1, ARC-520 API, the combination of the two,
or positive controls (combination of phorbol myris-
tate acetate and calcium ionophore A23187) at increas-
ing concentrations up to 250 μg/mL for ARC-EX1
and ARC-520 API. Incubation was at 37°C for 30
minutes, after which supernatants were analyzed for
histamine release and β-hexosaminidase release as a
measure of degranulation and LDH release as a mea-
sure of viability.
In Vitro Transporter Assays
The inhibition of membrane transporters OCT-2,
OCT-3, OAT-3, MATE1, and MATE2-K or bile acid
transporters ASBT, MRP1, MRP2, MRP3, NTCP,
and BSEP was evaluated in vitro at drug concentra-
tions up to 240 μg/mL by measuring the inhibition
of transporter-specific substrate transport across cell
membranes in cell lines stably expressing the respective
transporter as previously described.31–34
Results
All 9 cohorts (54 persons, half male and half female)
were enrolled and received the planned doses (Figure 1);
35 of 36 persons in the ARC-520 Injection treatment
group and 17 of 18 in the placebo group continued
through their day 90 follow-up call. One person in the
treatment group withdrew for personal reasons and 1 in
the placebo group because of travel conflicts; there were
no discontinuations for AEs. Most participants were
white; 4 were of Asian and 1 of African descent. Age
ranged from 18 to 53 years (mean, 26.85 years). ARC-
520 Injection doses evaluated were 0.01, 0.1, 0.3, 0.6,
1.2, 2.0, 3.0, and 4.0 mg/kg (see Table 2 for specific dose
and infusion rates for all cohorts).
Safety and Tolerability
Following single intravenous doses of ARC-520 Injec-
tion there were no clinically significant changes in ECG,
transaminases, troponin, hematology, electrolytes, or
urinalysis. No participant developed sensitivity to bee
venom based on changes in hymenoptera-specific IgE.
Vital signs were within normal limits in all participants
but 1, in whom there were no clinical symptoms, but
blood pressure as measured with an automated device
was shown to be decreased (58/24 mm Hg) 5 minutes
after receiving 0.3 mg/kg ARC-520 Injection. However,
the device used stopped working, and a manual reading
within 1 minute was normal (115/75 mmHg; heart rate,
75 bpm), as were subsequent pressures measured with
a different automated device; although recorded as an
AE, it is likely that this was machine failure.
One subject in cohort 3 (0.3 mg/kg ARC-520 In-
jection) was observed during overnight telemetry while
asleep (16 hours after dosing) to have a 7.9-second
pause associated with atrioventricular (AV) block;
 1 hour later an episode of Mobitz type I AV block
was noted; brief telemetry data available predosing re-
vealed Mobitz type I AV block prior to study dosing.
There were no associated ECG or vital sign abnormali-
ties; creatine kinase (CK) and troponin values were nor-
mal. Twenty-four-hour Holter monitoring conducted
9 days after dosing revealed a Wenckebach (Mobitz
type I) rhythm and a 2.5-second pause. The patient re-
ported a history of syncope prior to enrolling in the
study. A consulting cardiologist diagnosed hypervagal
syndrome, and there were no further medical interven-
tions.
Few changes in serum chemistry were reported
in subjects receiving ARC-520 Injection and placebo.
With the few laboratory abnormalities noted postdos-
ing, no pattern was apparent regarding time of occur-
rence or increasing incidence with increasing dose or
study treatment.
Complement. An increase in individual Bb levels (a
measure of alternative pathway activation) was de-
tected beginning in cohort 3 (1 subject) and cohort 4
(1 subject). A pattern of Bb increase was seen in the co-
hort average for groups 6, 7, 8, and 9. Increases were
mild, with no subject having a 4-fold or greater in-
crease over baseline, which would be considered clin-
ically significant.35 In all cases, the increase in Bb
occurred at 0.5 and 2 hours postdose. In addition, in co-
hort 9, there was a pattern toward a decrease in CH50
at 2 hours postdose in 4 subjects (3 treated with ARC-
520 Injection, 1 treated with placebo). All changes had
resolved by 6 hours after dosing.
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Figure 1. Study flow diagram. A total of 54 healthy adults (half were male and half were female) were enrolled and received the
planned doses; 35 of 36 persons in the ARC-520 Injection treatment group and 17 of 18 in the placebo group continued through
their day 90 follow-up call. One person in the treatment group withdrew for personal reasons and 1 in the placebo group because of
travel conflicts; there were no discontinuations for adverse events.
Cytokines. ARC-520 Injection administration led to
a transient increase in MCP-1 at 2 hours postdose.
The magnitude of the increase in MCP-1 (generally
around 10 times predose level) was similar at ARC-
520 Injection doses of 2.0 mg/kg and above, and this
increase was not seen for placebo-treated subjects. A
total of 12 subjects had a similar pattern of MCP-
1 increase, of whom 1 had symptoms of generalized
flushing, and 1 had symptoms of an urticarial rash.
A pattern of a lesser increase was seen for IL-8 and
MIP-1α. The level of increase for these 2 analytes
was slight (2.5 to 5 times predose levels). All increases
were transient, decreasing substantially by 6 hours post-
dose, reaching levels comparable to predose levels by
24 hours postdose. Finally, although the occurrence
of these modest increases appeared to be dose depen-
dent, the intensity did not increase with dose. None of
the other cytokines, including IFN-α2 (IFN-α), IL-1β,
IL-6, IL-12p40, IL-12p70, and TNF-α, showed any in-
creases posttreatment.
Adverse Events. There were no SAEs or AEs leading
to premature discontinuation of therapy or study dis-
continuation. Table 3 summarizes AEs by cohort and
in the placebo group. The incidence of all reported ad-
verse events was the same in the placebo and treatment
groups: 12 of 18 (67%) in the placebo group and 24
of 36 (67%) in the ARC-520 Injection treatment group.
There was no clear pattern of an increased rate or sever-
ity of AEs with dose escalation. The most commonly
reported AEs across all subjects were (in decreasing or-
der of frequency) headache, upper respiratory infection
(URI), somnolence, lethargy, and creatinine elevation.
Headaches, sore throats, and URIs were a common oc-
currence, as the study was conducted during the Aus-
tralian winter. Dizziness was reported in 2 subjects in
the 2 mg/kg group, was mild in both subjects, and was
not accompanied by any vital sign changes. One inci-
dent of dizziness was reported to resolve in less than a
minute; the other lasted 47 minutes. These were not as-
sociated with ECG or telemetry changes. Mild drowsi-
ness was noted in 4 subjects and was not thought to
be related to study treatment but rather early-morning
predose administration of diphenhydramine. In 3 sub-
jects there were transient creatinine elevations. One sub-
ject, a 2- year-old black man who received placebo,
had a predose creatinine of 0.86 mg/dL and the follow-
ing postdose levels; 0.814 mg/dL, 4 hours; 1.33 mg/dL,
12 hours; 0.916 mg/dL, 24 hours; .927 mg/dL, 72 hours.
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n = 18 n = 4 n = 4 n = 4 n = 4 n = 4 n = 4 n = 4 n = 4 n = 4
Adverse event Number of subjects with adverse events related (not related) to study drug
Upper respiratory
tract infection







Headache 3 (2) 1 (1) (1) 1









Oropharyngeal pain (1) (1)
Dry throat (1)




Pain in extremity (1)
Catheter site bruise (1)
Contusion (1) (1)
Laceration (1)
Creatinine increase 1 2
Relationship Number of subjects with moderate or severe adverse events
Severe All
















PBO, placebo; DPH, diphenhydramine; n, number of subjects; blank cell, no AE reported.
One subject, a 31-year-old white woman who re-
ceived ARC-520 Injection at 4 mg/kg, had a pre-
dose creatinine of 0.77 mg/dL and the following
postdose levels: 0.77 mg/dL, 4 hours; 1.78 mg/dL,
12 hours; 0.848 mg/dL, 24 hours; 0.825 mg/dL,
48 hours; 0.814 mg/dL, 72 hours. The third subject,
a 20-year-old white woman who also received ARC-
520 Injection at 4 mg/kg, had a predose creatinine
of 1.188 mg/dL and the following postdose levels;
1.4 mg/dL, 4 hours; 2.29 mg/dL, 12 hours; 1.17 mg/dL,
24 hours; 1.09 mg/dL, 48 hours; 1.05 mg/dL, 72 hours.
There were no associated adverse changes in blood urea
nitrogren, electrolytes, or CK. Urinalysis for all 3 sub-
jects were within normal limits at 4, 12, and 24 hours
without hematuria, proteinuria, or tubular casts. To
evaluate if creatinine increases were related to inhibi-
tion of renal transporters, in vitro studies were per-
formed. ARC-520 Injection did not inhibit any of 5
evaluated renal transporters (OCT-2, OCT-3, OAT-3,
MATE1, and MATE2-K).
Several ARC-520 Injection–treated subjects showed
mild, transient bilirubin elevations 4 hours postadmin-
istration, an effect that was not observed in placebo
subjects. An in vitro evaluation of bile acid trans-
porters showed no inhibition of ASBT, MRP1, MRP2,
or MRP3, partial inhibition of NTCP at high assay
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concentrations (close to the Cmax in plasma), and po-
tent inhibition of BSEP. However, because of the re-
dundant nature of bile acid transport, it is not clear that
bile acid transporter inhibition was the cause of the ob-
served bilirubin increases.
Suspected hypersensitivity reactions were observed
in 2 ARC-520 Injection–treated subjects (1 generalized
flushing at 0.3 mg/kg and 1 urticarial rash at 2.0 mg/kg)
who were not pretreated with an antihistamine. The
urticarial rash was treated with intravenous promet-
hazine but was noted to be resolving before the treat-
ment was administered. No further hypersensitivity
reactions were observed after patients were pretreated
with an oral antihistamine (cohorts 7–9) despite pro-
gressing to higher doses.
Mast Cell Degranulation Studies
After 2 subjects developed hypersensitivity reactions,
1 in cohort 3 and 1 in cohort 6, in vitro studies with
rat and human mast cells were performed. These stud-
ies indicated that ARC-520 Injection induces dose-
dependent degranulation and histamine release, for
which the major trigger is the ARC-EX1 component,
with a lower level of degranulation induced by the API
component (Figure 2). Histamine release equivalent to
that produced by the positive control, or nearly so,
occurred at concentrations  2 ug/mL ARC-EX1 in-
jection. This is below the Cmax for MLP in patients in
cohorts 3–9. The effects observed were specific for de-
granulation activity and not cellular cytotoxicity.
Pharmacokinetics
Pharmacokinetic results indicate that the siRNA com-
ponents (AD0009 and AD0010) circulated with a short
half-life of 3–5 hours (Table 4, Figure 3). The MLP ex-
cipient component had a somewhat longer half-life of
8–10 hours. Dose proportionality was evaluated using
a log-log regression model. Exposure to the ARC-520
components MLP, AD0009, and AD0010 increased
proportionally with dose (Table 5). Ninty-five percent
confidence intervals for PK parameters for this study
were extremely narrow, indicatingminimal interindivid-
ual variability. As a consequence, the slope often did not
include 1.0 in the confidence interval. However, with
point estimates varying between 1.0 and 1.08, this de-
viation from linearity was considered minimal.
Discussion
Because, although effective at suppressing viral DNA
and reducing liver inflammation, existing HBV ther-
apies rarely result in sustained functional cures off
therapy, new therapies are needed that can lead to a
high percentage of functional cures (HBsAg clearance).
ARC-520 Injection is the first RNAi therapeutic tar-
geting HBV to enter clinical testing. It is designed to
Figure 2. Induction of histamine release from rat peritoneal
mast cells in vitro. Histamine concentrations (nM) ± SD in the
supernatant of cells is shown for various treatments at 10 and
30 minutes of incubation.Both ARC-520 Injection (C) and ARC-
EX1 (A) but not ARC-520 API (B) induced mast cell degranula-
tion and histamine release in a dose-dependent manner. Positive
controls included were immunoglobulin E–dinitrophenol com-
plex (IgE-DNP) and compound 48/80. ARC-520 API was eval-
uated at higher doses than ARC-EX1, and maximum histamine
release was observed at ARC-EX1 concentrations of 10 μg/mL
and greater. As a control for total cellular content, mast cells
treated with Triton X-100 led to release of 3.18 ± 0.26 nM his-
tamine (dotted lines); this process induces cell lysis and should
not be considered an activation event.
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Table 4. Summary of Pharmacokinetic Parameters Following Administration of ARC-520 Injection
Treatment Group (n = 4) Analyte AUC0–inf (μg·h/mL) Cmax (μg/mL) T1/2 (h)
Cohort 1 MLP 2.5 (0.4, 2.0–2.9) 0.2 (0.03, 0.2–0.3) 8.70 (2.1, 6.16–10.80)
0.01 mg/kg AD0009 0.5 (0.05, 0.4–0.5) 0.1 (0.02, 0.1–0.1) 2.68 (0.4, 2.32–3.25)
AD0010 0.7 (0.2, 0.5–0.9) 0.1 (0.02, 0.1–0.2) 3.48 (0.7, 2.79–4.40)
Cohort 2 MLP 21.2 (2.7, 18.4–23.7) 2.3 (0.4, 2.0–3.0) 7.03 (0.8, 6.26–7.92)
0.10 mg/kg AD0009 6.4 (1.5, 4.6–8.0) 1.1 (0.2, 0.9–1.5) 3.41 (0.5, 2.63–3.71)
AD0010 8.4 (2.1, 5.8–10.6) 1.2 (0.2, 1.0–1.5) 4.33 (0.8, 3.20–5.14)
Cohort 3 MLP 70.9 (11.5, 59.5–86.5) 6.4 (0.6, 5.9–7.1) 8.32 (2.2, 6.36–11.60)
0.30 mg/kg AD0009 18.0 (2.2, 15.7–21.0) 3.1 (0.2, 2.9–3.4) 3.48 (0.6, 2.93–4.29)
AD0010 23.2 (2.8, 20.2–27.0) 3.3 (0.4, 2.9–3.8) 4.39 (0.6, 3.62–5.11)
Cohort 4 MLP 157.8 (49.6, 127.8–231.5) 13.2 (2.7, 11.1–16.9) 9.26 (2.8, 7.00–13.30)
0.60 mg/kg AD0009 34.0 (5.8, 27.5–39.8) 6.1 (1.4, 5.0–8.0) 3.62 (0.5, 2.91–3.92)
AD0010 42.6 (7.7, 33.6–51.3) 6.5 (1.2, 5.4–8.0) 4.15 (0.2, 3.93–4.34)
Cohort 5 MLP 297.3 (66.3, 231.9–386.9) 25.4 (4.4, 21.4–31.6) 7.45 (1.1, 6.40–8.73)
1.20 mg/kg AD0009 77.5 (15.2, 66.5–99.7) 11.4 (1.9, 8.8–13.3) 4.00 (0.2, 3.83–4.13)
AD0010 108.3 (26.1, 89.8–146.7) 13.3 (2.2, 10.4–15.4) 4.40 (0.2, 4.22–4.72)
Cohort 6 MLP 634.9 (131.7, 553.2–831.8) 50.3 (3.8, 46.6–55.4) 8.85 (1.8, 6.70–10.7)
2.00 mg/kg AD0009 125.4 (37.8, 100.5–181.3) 21.0 (1.8, 19.2–23.2) 3.82 (0.6, 3.46–4.72)
AD0010 190.4 (46.0, 162.3–258.5) 25.5 (1.1, 24.3–26.7) 4.19 (1.0, 3.49–5.53)
Cohort 7 MLP 528.1 (62.6, 452.1–590.9) 47.8 (5.5, 40.2–52.2) 7.68 (1.5, 5.48–8.81)
2.00 mg/kg + DPH1 AD0009 138.6 (18.2, 117.1–161.4) 21.9 (2.3, 20.1–25.0) 3.86 (0.1, 3.72–3.99)
AD0010 196.2 (21.8, 171.9–223.7) 26.1 (2.9, 22.6–29.6) 4.19 (0.2, 3.95–4.37)
Cohort 8 MLP 968.7 (116.8, 858.2–1102.4) 65.5 (3.3, 61.2–69.3) 9.84 (1.7, 7.44–11.40)
3.00 mg/kg + DPH1 AD0009 221.8 (22.9, 198.0–252.2) 34.4 (1.5, 33.0–35.8) 3.73 (0.2, 3.61–3.94)
AD0010 292.5 (23.6, 280.1–327.8) 35.6 (1.3, 34.5–37.1) 4.23 (0.2, 4.06–4.54)
Cohort 9 MLP 1236.4 (207.1, 969.7–1457.6) 77.8 (4.1, 72.4–82.1) 10.3 (2.0, 8.65–13.20)
4.00 mg/kg + DPH1 AD0009 374.3 (29.7, 340.3–408.2) 48.8 (3.8, 46.2–54.3) 3.93 (0.3, 3.68–4.60)
AD0010 490.9 (146.4, 389.5–706.9) 44.3 (1.3, 42.7–45.6) 4.68 (0.5, 4.04–5.23)
Arithmetic mean (SD,min–max) values for select parameters of the excipient MLP and siRNAs AD0009 and AD0010 contained in ARC-520 Injection
are listed.
n, number of subjects per PK cohort;DPH, diphenhydramine;MLP,melittin-like peptide,AD0009,AD0010: siRNAs targeted against HBV.The ratio (on
a weight basis) of MLP:AD0009:AD0010 in ARC-520 Injection is 2:1:1, dose level is in total API (sum of siRNAs) administered.
Table 5. Dose Proportionality of ARC-520 Injection Using Log-Log Regression
Analyte PK Parameter r² Estimate of β Standard Error 95% Confidence Interval
MLP Cmax 0.995 1.00 0.01 0.98–1.03
MLP AUCinf 0.990 1.05 0.02 1.01–1.08
AD0009 Cmax 0.994 1.00 0.01 0.98–1.03
AD0009 AUCinf 0.991 1.08 0.02 1.05–1.12
AD0010 Cmax 0.995 1.00 0.01 0.97–1.02
AD0010 AUCinf 0.990 1.08 0.02 1.04–1.11
reduce all RNA transcripts derived from viral cccDNA,
leading to a reduction in viral antigens, as well as HBV
DNA. Viral antigens, especially HBsAg, have been
implicated in the suppression of the immune sys-
tem, leading to immune exhaustion and persistence of
chronicity. RNAi therapy leading to reductions in vi-
ral antigens may allow for immune reconstitution and
functional cure, defined as sustained loss of HBsAg
with or without seroconversion.
In this first-in-human phase 1 study that assessed
the safety, tolerability, and pharmacokinetics of
intravenously administered ARC-520 Injection in
healthy volunteers, ARC-520 Injection was well toler-
ated with an acceptable safety profile up to a dose of
4 mg/kg. This is supported by the finding that the
incidence and severity of AEs were the same in
placebo- and ARC-520 Injection–treated subjects.
ARC-520 Injection, and more specifically its peptide
component, was found to cause mast cell degran-
ulation and histamine release in vitro. Although 2
subjects treated with ARC-520 Injection exhibited
mild or moderate hypersensitivity reactions, no further
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Figure 3. Mean plasma concentration-versus-time profiles
for ARC-520 delivery component melittin-like peptide (MLP)
(A) and siRNAs AD0009 (B), and AD0010 (C). Plasma concen-
trations less than the limit of quantitation (LOQ) of the assay
were designated a value of zero for pharmacokinetic analysis and
included in the calculation of arithmetic means. All components
showed a relatively short half-life of 3–5 hours for siRNAs and
8–10 hours for MLP, respectively. Exposure increased approxi-
mately linearly with dose.Given the anticipated dosing frequency
of once every 4 to 6 weeks, the risk of drug accumulation is
minimal.
hypersensitivity reactions were observed following ini-
tiation of oral antihistamine pretreatment, supporting
this hypothesis and also indicating that sequelae are
easily prevented.
Although transient increases in creatinine with no
other changes in laboratory parameters were observed
in 3 study participants, including 1 who received
placebo, the rapid creatinine decrease and return to
baseline within 24 hours lead to the conclusion that
it is unlikely to be related to renal tubule injury.
Although temporal inhibition of tubular creatinine
secretion or an effect of ARC-520 Injection on
glomerular hemodynamics is a possibility, the notable
elevation in 1 placebo participant makes it more likely
that a cooked protein-containingmeal after fasting con-
tributed to the transient elevation in creatinine. A sim-
ilar effect was seen in a study in healthy volunteers
consuming cooked meat after fasting.36 In addition,
in vitro studies showed that ARC-520 Injection did
not inhibit any of 5 evaluated renal transporters, sup-
porting this assessment. Although the mild bilirubin
elevations observed in ARC-520 Injection–treated par-
ticipants 4 hours postadministration were not seen in
those given placebo, the clinical significance of these
observations is considered minimal based on the mild-
ness and transient nature of the increases and given that
this drug is expected to be delivered once monthly or
less. Laboratory signs of innate immune activation were
assessed through measurement of complement and cy-
tokine activation in plasma. Low-level complement in-
creases were all transient and minimal, indicating that
their clinical consequence would be questionable.35 The
same is true of the asymptomatic low-level cytokine
increase in a few ARC-520 Injection–treated subjects.
Taken together, this indicates that ARC-520 Injection
has a low potential to activate the innate immune
system.
Pharmacokinetics of the siRNA andMLP excipient
components contained in ARC-520 Injection showed a
relatively short half-life of 3–5 and 8–10 hours, respec-
tively. Exposure increased approximately linearly with
dose. A long duration of activity of more than 4 weeks
has been demonstrated after a single dose of ARC-
520 Injection in preclinical animal studies18 and in pa-
tients with chronic HBV.37 The persistence of activity
significantly beyond the period of plasma exposure is
because of the unique RNAi mechanism, in which a
small amount of siRNA guide strand can persist and
be active within the RNA induced silencing complex
(RISC) in the cytoplasm of target cells for extended
periods. Given that ARC-520 Injection is expected to
be dosed infrequently, systemic exposure to the compo-
nents of ARC-520 Injection can be considered episodic
and brief in clinical practice, with a minimal risk of ac-
cumulation under multiple-dose conditions.
In summary, ARC-520 Injection showed an accept-
able tolerability profile in this single-dose study in
healthy volunteers. Pretreatment with an oral antihis-
tamine is recommended for future studies based on the
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findings of this study and supporting in vitro data in-
dicating direct stimulation of mast cell degranulation.
Single- and multidose studies in patients with chronic
HBV are currently ongoing.
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